团队负责人：饶勇 研究员

饶勇，研究员，药学院测试中心主任，中山大学博士。研究方向聚焦肝脏代谢调控与重大肝病海洋新药发现研究。以第一/通讯作者发表SCI论文50余篇，包括肝脏领域顶刊Hepatology (IF16.8), Nature子刊Exp Mol Med（IF12.9）、APSB （IF14.7，3篇）、Pharmacological Research（IF10.5，2篇）、J Med Chem（IF7.3，8篇）, Br J Pharmacol (IF9.473，3篇)等。主持国家自然科学基金面上项目等3项，海南省重点研发项目等项目10余项；核心成员参与国家重点项目、广州市科技民生重大专项等项目，申请国家发明专利10项，已授权7项。

团队介绍：

你有没有想过当你食用高糖、高脂、或膳食纤维时，肝脏代谢会呈现什么各自不同的变化，这些变化的核心基础是什么？对应的表型变化的核心基因网络是什么？想清楚理解机体如何响应不同物质变化，更好了解与管理自身健康，欢迎加入肝脏研究团队。肝脏代谢异常导致肝脏病变与系统性重大疾病发生。团队致力于肝脏代谢研究，通过模拟临床肝脏疾病的病变，分别从代谢维度剖析肝脏代谢调控的核心细胞亚群、关键代谢物、核心机制与靶点；围绕蓝色海洋药物资源，从表型、靶点层面快速精准鉴别海洋活性分子，指导海洋原创药物高效发现。

研究方向：

（1）临床患者/动物模型导向的内源性活性代谢标志物发现；

（2）肝脏代谢调控核心机制与原创靶点研究；

（3）重大肝病海洋新药分子精准筛选与转化研究；

代表性成果：

1. Rao Y^{1, *}, Su R¹, Cao WJ¹, Chen Y, Huang SH, Wu JJ, Henstridge DC, Huang LS, Liu J, Liu FF, Jiang ZP, Xu CJ, Huang ZS, Ye JM*, Huang L*. HSP72 Interacts with PRDX6 to Deubiquitinate Mitochondrial PINK1, Activating Mitophagy to Treat MASLD. Hepatology. 2026. Accepted, IF16.8

2. Rao Y*, Su R, Fu HL, Liu J, Cao WJ, Yang ZC, Zhang C, Su XX, Liu FF, Jiang ZP, Xu CJ, Xiong WD, Luo HB, Huang L. Identification of flupirtine as a candidate against liver fibrosis in mice: Preserving mitochondria quality by suppressing calpain 1/complex I/mtROS axis via targeting asparagine synthase. Acta Pharm Sin B, 2026. Accepted, IF14.7

3. Cao WJ, Su R, Fu HL, Wu JJ, Huang LS, Liu FF, Liu J, Jiang ZP, Xu CJ, Rao Y*, Huang L*. Supplementation of L-aspartate corrects MASLD and MASH in mice by inhibiting platelet-hepatocyte interaction-mediated mitochondrial fragmentation via the ATP-P2X7-NEK7-DRP1 axis. Exp Mol Med 2026, 58(2): 533-547. Nature子刊，IF12.9

4. Jiang Z, Chen Y, Wu S, Wang J, Liu F, Liu J, Xu C, Li W, Rao Y*, Huang L*. Discovery of Marine Highly Congested Polycyclic Isodhilarane-Type Meroterpenoids as Potential Leads for Treating Liver Fibrosis by Activating the HSF1/AMPK Metabolic Axis. J Med Chem 2026, 69(4): 4346-4360. 药物化学TOP期刊, IF7.3

5. Gu S, Yang G, Bian H, Yang F, Zhang Y, Huang Y, Su R, Zhang H, Zhao X, Liu J, Huang S, Huang L, Hou B, Rao Y, Xu C. Development of a Highly Selective Ferroptosis Inducer Targeting GPX4 with 2-Ethynylthiazole-4-carboxamide as Electrophilic Warhead. J Med Chem 2025, 68(3): 3309-3323. 药物化学TOP期刊, IF7.3

6. Ding Y, Lv F, Chen Y, Liu Z, Ma Y, Li SR, Yin DJ, Wen J, Rao Y, Huang J, Lai ZW. Brønsted acid-catalyzed asymmetric [3 + 3] cyclization of para-quinamines: Access to 6/6/6/6-fused tetracyclic 1,2,4-triazinanes. Chin Chem Letts 2025, 112288. IF8.9

7. Liu Z, Ding Y, Chen MB, Lv F, Xiao T, Liu WB, Wan BR, Huang L, Rao R*, Lai ZW*. [2 + 3] Cycloaddition of para-Quinamines and para-Quinols with C,N-Cyclic Azomethine Imines: Access to 6/5/6/6-Fused Tetracyclic Pyrazolidines. Org Lett 2025, 27(24): 6257–6263. IF5.0

8. Su R, Fu HL, Zhang QX, Wu CY, Yang GY, Wu JJ, Cao WJ, Liu J, Jiang ZP, Xu CJ, Rao Y*, Huang L*. Amplifying hepatic L-aspartate levels suppresses CCl4-induced liver fibrosis by reversing glucocorticoid receptor β-mediated mitochondrial malfunction. Pharmacol Res 2024, 206:107294. IF10.5

9. Rao Y ^1,*, Su R¹, Wu CY¹, Chai XX, Li JJ, Yang GY, Wu JJ, Fu TT, Jiang ZP, Guo ZK, Xu CJ*, Huang L*. Identification of a natural PLA2 inhibitor from the marine fungus Aspergillus sp. c1 for MAFLD treatment that suppressed lipotoxicity by inhibiting the IRE-1α/XBP-1s axis and JNK signaling. Acta Pharm Sin B 2024, 14(1): 304-318. IF14.8

10. Wu CY, Chen Y, Chen MT, Fu TT, Liu J, Liu FF, Xu CJ, Li WS, Li BL, Jiang ZP, Rao Y*, Huang L*. Natural linoleic acid from marine fungus Eutypella sp. F0219 blocks KEAP1/NRF2 interaction and ameliorates MASLD by targeting FABP4. Free Radic Biol Med 2024, 224:630-643.IF8.3

11. Zhou Q, Le M, Yang Y, Wang W, Huang Y, Wang Q, Tian Y, Jiang M, Rao Y*, Luo HB*, Wu Y*. Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis. Acta Pharm Sin B 2023, 13(3):1180-1191. IF14.8

12. Li C, Xu YH, Hu YT, Zhou X, Huang ZS, Ye JM, Rao Y. Matrine counteracts obesity in mice via inducing adipose thermogenesis by activating HSF1/PGC-1α axis. Pharmacol Res. 2022, 177: 106136. IF10.5

13. Yan XL, Pan YH, Fan RZ, Song QQ, Li S, Huang JL, Li W, Huang D, Yuan FY, Tang GH, Rao Y, Huang ZS, Yin S. Discovery of the First Raptor (Regulatory-Associated Protein of mTOR) Inhibitor as a New Type of Antiadipogenic Agent. J Med Chem 2023, 66(8): 5839-5858. 药物化学TOP期刊, IF8.1

14. Rao Y^*, Li C, Hu YT, Xu YH, Song BB, Guo SY, Jiang Z, Zhao DD, Chen SB, Tan JH, Huang SL, Li QJ, Wang XJ, Zhang YJ, Ye JM^*, Huang ZS^*. A novel HSF1 activator ameliorates non-alcoholic steatohepatitis by stimulating mitochondrial adaptive oxidation. Br J Pharmacol 2022, 179(7):1411-1432. 药理学TOP期刊，IF9.743

15. Rao Y^{1, *}, Kuang Z¹, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z, Liu X, Li C, Chen S, Ye J, Huang ZS*, Lu YJ*. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes 2021, 13(1): 1-19. IF12.2

欢迎基础医学、药理学、化学生物学、生物信息学等专业加入团队，共同发展。